Alto Neuroscience (ANRO) Expected to Post Quarterly Earnings on Wednesday

Alto Neuroscience (NYSE:ANRO) is expected to be announcing its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.6735) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, analysts expect Alto Neuroscience to post ($2.69) EPS for the current fiscal year and ($2.92) EPS for the next fiscal year.

Alto Neuroscience Stock Performance

Shares of ANRO opened at $23.19 on Wednesday. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 52-week low of $10.62 and a 52-week high of $37.48. The stock has a 50 day moving average price of $27.77 and a 200 day moving average price of $24.22. The company has a market capitalization of $910.13 million, a price-to-earnings ratio of -9.60 and a beta of 1.42.

Analysts Set New Price Targets

Several research firms have commented on ANRO. Zacks Research raised Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. BTIG Research lifted their target price on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. HC Wainwright upped their price target on shares of Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, October 19th. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Finally, Wedbush raised their price objective on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $37.88.

Insider Activity

In other news, CFO Nicholas Smith sold 110,830 shares of the stock in a transaction that occurred on Tuesday, September 29th. The stock was sold at an average price of $26.58, for a total transaction of $2,945,861.40. Following the completion of the transaction, the chief financial officer directly owned 24,060 shares of the company’s stock, valued at approximately $639,514.80. This represents a 82.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 11.25% of the company’s stock.

About Alto Neuroscience

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and central nervous system disorders. The company combines neuroscience research, clinical data and biomarker-based approaches to identify patients who may be more likely to respond to specific treatments.

Alto Neuroscience’s investigational pipeline includes therapies intended to address conditions such as major depressive disorder, bipolar depression, schizophrenia and associated cognitive impairment.